For the third straight quarter, AbbVie has jacked up its revenue forecast for 2025. The Illinois drugmaker has raised its guidance by $400 million, now expecting sales to reach $60.9 billion. | ...

For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option. | ...

Takeda tightened its pipeline in the third quarter. Innovent Biologics reported a head-to-head win against semaglutide in a Chinese phase 3 trial. | Takeda tightened its pipeline in the third quarter.

As momentum for Biogen’s newer drugs for neurological disorders builds at a slow and steady pace, it appears that the company ...

CSL Seqirus, the vaccine unit of Australian biotech CSL, has signed a pact to provide Saudi Arabia with cell-based influenza shots and help establish its production in-country. The move forms part of ...

During BMS’ earnings call Thursday, CEO Chris Boerner, Ph.D., described Cobenfy as “delivering steady growth.” But the first-in-class drug still has a long way to go to fulfill its promise as a ...

With vaccine sales on the decline, these are tough times for Merck to launch its new pneumococcal shot Capvaxive. | With ...

Worth noting, CVS Caremark—the biggest PBM in the U.S.— announced in May that it would make Novo Nordisk’s rival drug Wegovy ...

Alnylam’s closely watched launch of its rare disease drug Amvuttra continued to outpace Wall Street expectations. | Riding its March expansion into the heart condition of ATTR-CM, sales of Amvuttra ...

The FDA has revealed a set of measures designed to increase the availability of biosimilars in the U.S. and in turn reduce ...

A myasthenia gravis treatment revolution has taken place in the past four years, spurred by an initial approval for argenx’s ...

After a progression-free survival win last year raised hopes for the combo's potential in hepatocellular carcinoma, an overall survival miss brings the study to a close.